A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [ 18 F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer

ConclusionsFMAU tracer was able to detect bone metastases in CRPC patients but uptake was highly variable in bony lesions. Zoledronic acid did not produce an appreciable change in scans. Future investigations of FMAU tracer as a marker of early response in CRPC is recommended.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research